Liquid purification or separation – Processes – Liquid/liquid solvent or colloidal extraction or diffusing...
Reexamination Certificate
2002-06-21
2004-08-17
Kim, John (Department: 1723)
Liquid purification or separation
Processes
Liquid/liquid solvent or colloidal extraction or diffusing...
C210S321790, C210S321800, C210S321810, C210S321880, C210S321890, C210S321900, C210S433100, C210S500230, C210S650000, C422S044000, C604S004010
Reexamination Certificate
active
06776912
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to a hemodiafiltration system for treating blood, comprising a membrane module having a cylinder-shaped housing with a longitudinal extent, in which housing is included a bundle of hollow-fiber membranes having semipermeable walls capable of supporting fluid flow through their lumina. The ends of the hollow-fiber membranes are embedded in a manner in first and second sealing compounds joined to the housing inner wall in a fluid-tight manner and are arranged in the direction of the longitudinal extent. There is a dialyzate space into which a dialyzate inlet arrangement and a dialyzate outlet arrangement open, as well as a substituate space into which a substituate inlet arrangement opens, a means for delivering a dialyzate with a defined volume stream into the dialyzate space via the dialyzate inlet arrangement, a means for withdrawing the dialyzate from the dialyzate space via the dialyzate outlet arrangement, and a means for delivering a substituate with a defined volume stream into the substituate space via the substituate inlet arrangement. The membrane module is implemented as an integrated unit for blood treatment, filtration of the substituate, and mixing of the substituate with the blood. The substituate and dialyzate spaces are separated from each other in a fluid-tight manner via a continuous dividing wall. The invention furthermore relates to a membrane module for hemodiafiltration.
2. Discussion of Related Art
Hemodiafiltration is a combined membrane-based process for blood purification in which hemodialysis and hemofiltration are conducted concurrently. This process combines the advantages of convective substance transport in hemofiltration with those of diffusion in hemodialysis. In hemofiltration, blood is passed along one side of the membrane of a hemofilter and a portion of the blood liquid is withdrawn through the membrane by ultrafiltration. This partial stream is replaced by a sterile and pyrogen-free substitution liquid, or substituate, that is delivered to the extracorporeal blood stream either upstream from the hemofilter in the form of pre-dilution or downstream from the hemofilter in the form of post-dilution. In addition, in hemodiafiltration the usual hemodialysis is also conducted, wherein dialyzate is passed along the other side of the membrane of the hemodialyzer such that substances usually eliminated with the urine can be removed through the membrane.
The combination of diffusive substance transport with convective substance transport in hemodiafiltration permits the advantageous removal of more than only substances from the blood having a low molecular weight that are usually eliminated with the urine. Slowly diffusing medium-sized molecules with molecular weights from about 1 to 55 kD profit especially from the convective substance transport, and that is all the more so as these molecules increase in size and as the filtrate stream through the membrane increases. At about 60 kD, the membranes are intended to be essentially impermeable, so that the patient does not pass more than 4 g of protein from the blood into the dialyzate during a 4-hour treatment.
In the conventional hemodialysis process, only the amount of liquid the patient has taken in between the dialysis treatments is removed from the blood via the dialysis membrane as ultrafiltrate. The amount of liquid removed in this process is about 6 to 8% of the blood volume stream. In conducting current hemodialysis processes, so-called volume-controlled dialysis machines are generally used. They control the net amount of liquid removed according to the preset net filtration by balancing the dialyzate stream fed to the dialyzer with the dialyzate stream withdrawn from the dialyzer.
In hemodiafiltration, on the other hand, the amount of ultrafiltrate is significantly higher, from about 20 to 30% of the blood volume stream, due to the liquid fraction needed to increase the convective transport through the membrane. In the end, the net amount of liquid withdrawn from the patient is the same as that in conventional hemodialysis. The amount of liquid exceeding that needed to increase the convective transport is, as noted, replaced by a substituate.
To conduct hemodiafiltration processes, modified dialysis machines are generally used that permit control of the ultrafiltration rates and balance the ultrafiltration and substituate volume streams.
Different requirements are usually imposed with respect to the purity of the dialyzate and substitution liquids. The dialyzate can be prepared online from fresh water and an electrolyte concentrate, where the fresh water is normally germ-free and the electrolyte concentrate inherently sterile. The substitution liquid itself can be prepared online from the dialyzate, but it is not generally required that the dialyzate prepared online is absolutely sterile and free of endotoxins, pyrogens and CIS.
Endotoxins are cell remnants of dead bacteria. The endotoxin concentration is usually determined using the so-called LAL test, a biological assay such as that manufactured by BioWhittaker, Inc., for example. Pyrogens are temperature-elevating substances. When infused in rabbits, for example, they cause an increase in body temperature. Pyrogens can include endotoxins and exotoxins. The latter are produced by living bacteria. In human blood, these substances lead to stimulation of monocytes that themselves produce cytokines and thus trigger a cascade of additional cell stimulations. Today, endotoxins, exotoxins, pyrogens, and other substances from the dialyzate that stimulate the blood are grouped under the abbreviation CIS (cytokine inducing substances). One of the relevant cytokines produced by stimulation of stimulated monocytes is interleukin 6 (IL 6). The determination of CIS by detection of IL 6 is described in B. L. Jaber et al., Blood Purif. 1998, Vol. 16, pp. 210-219, for example.
For this reason, the dialyzate for preparing the substitution liquid should be converted to the sterile and ideally CIS-free state, using a filter, for example. Of course, the substitution liquid prepared in this manner can also be used itself as dialyzate. Modem dialysis machines generally include a facility with which the dialyzate is filtered online such that it has an endotoxin concentration of less than 0.5 EU per ml of dialyzate. As a result, patients experience almost no pyrogen reactions, even in the case of so-called high-flux dialysis, which are frequently observed with dialyzate contaminated with endotoxins. However, with an endotoxin concentration of <0.03 EU/ml, which is the detection limit of the conventional LAL tests, CIS might still be present in the dialyzate. The requirement for CIS-free dialyzate is therefore more stringent than that for LAL-negative dialyzate.
In EP-A 692 269, a hemodiafiltration apparatus is described with two blood filters connected in series. The blood filters each contain membranes, one side of which is subjected to a flow of blood to be purified and the other side to dialyzate flow. The dialyzate fed to the hemodiafiltration apparatus was previously passed through a sterile filter. In the apparatus described in EP-A 692 269, a transfer of dialyzate as a substitution liquid directly into the blood takes place in one of the two blood filters in the direction of the blood flow, due to the positive transmembrane pressure set at this point via the membrane of this blood filter. A negative transmembrane pressure is generated in the second blood filter, where separation of a portion of the blood liquid and removal into the dialyzate of substances normally eliminated with the urine take place via diafiltration.
Such hemodiafiltration apparatus with blood filters connected in series are complex in operation and can generally not be used in commercially available dialysis machines due to the design and the special and complex controls associated with it.
EP-A 451 429 also discloses a hemodiafiltration apparatus having two membrane modules connected in series. In this case,
Kim John
Membrana GmbH
LandOfFree
Hemodiafiltration system and method does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hemodiafiltration system and method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hemodiafiltration system and method will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3327015